Last reviewed · How we verify
NCT04292327: 2019-nCoV
Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus
trial in Pneumonia Caused by Human Coronavirus in 400 participants. Status unknown.
30 April 2020
Quick facts
| Lead sponsor | Fujian Provincial Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 1 January 2020 |
| Primary completion | 30 April 2020 |
| Estimated completion | 31 July 2020 |
| Sites | 1 location across China |
Conditions studied
- Pneumonia Caused by Human Coronavirus — all drugs for Pneumonia Caused by Human Coronavirus →
Sponsor
Fujian Provincial Hospital
Who can join
Adults 18 to 75, any sex, with Pneumonia Caused by Human Coronavirus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Objects: The purpose of this study was to observe the characteristics of morbidity, disease progression and therapeutic effects of 2019-novel coronavirus pneumonia patients with different clinical types. Method: A single center, retrospective and observational study was used to collect COVID-19 patients admitted to Wuhan Infectious Diseases Hospital (Wuhan JinYinTan Hospital) from January 2020 to March 2020. The general information, first clinical symptoms, hospitalization days, laboratory examination, CT examination, antiviral drugs, immune enhancers, traditional Chinese medicine treatment and other clinical intervention measures were recorded, and the nutritional status and prognosis of the patients were recorded. confirm COVID-19 's disease progression, clinical characteristics, disease severity and treatment effects. To compare the characteristics of disease progression, clinical features, disease severity and therapeutic effect of different types of COVID-19. Outcomes: The characteristics of disease progression, clinical features, disease severity and therapeutic effect of different types of COVID-19. Conclusion: The characteristics of disease progression, clinical features and therapeutic effect of different types of COVID-19.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Risk factors for disease severity in COVID-19 patients: A single-center retrospective study.
Xu J, Cai Y, Li M, Li Q, et al · · 2021 · cited 1× · PMID 36943821 · DOI 10.1016/j.jointm.2021.03.001
Verify or expand the search:
- PubMed search for NCT04292327
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Fujian Provincial Hospital trials
Trials by the same sponsor.
- NCT07471763 — Prospective Lifespan Cohort of Myocardial Infarction · not yet recruiting
- NCT07290764 — Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic T · enrolling by invitation
- NCT07251114 — AI-assisted Endoscopic Ultrasound Grading of Early Esophageal Cancer Invasion Depth: A Multicenter, Prospective, Randomi · NA · recruiting
- NCT06564506 — Electroacupuncture for Preventing Postoperative Delirium in Older Adults Undergoing Total Knee Arthroplasty · NA · not yet recruiting
- NCT07380542 — Dynamic Magnesium Replacement Strategies and 28-Day Mortality in Non-Cardiac Critically Ill Patients With Hypomagnesemia · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04292327 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Provincial Hospital
- Last refreshed: 3 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04292327.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing